Devazepide

Devazepide[1] (L-364,718, MK-329) is benzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity for GABAA receptors and instead acting as an CCKA receptor antagonist.[2] It increases appetite and accelerates gastric emptying,[3][4] and has been suggested as a potential treatment for a variety of gastrointestinal problems including dyspepsia, gastroparesis and gastric reflux.[5] It is also widely used in scientific research into the CCKA receptor.[6][7]

Devazepide
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.208.547
Chemical and physical data
FormulaC25H20N4O2
Molar mass408.452 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Synthesis

Devazepide is synthesised in a similar manner to other benzodiazepines.[8][9]

See also

References
  1. US Patent 4820834
  2. Hill, DR; Woodruff, GN (Sep 1990). "Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260". Brain Research. 526 (2): 276–83. doi:10.1016/0006-8993(90)91232-6. PMID 2257485.
  3. Cooper, SJ; Dourish, CT (Dec 1990). "Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding". Physiology & Behavior. 48 (6): 849–57. doi:10.1016/0031-9384(90)90239-z. PMID 1982361.
  4. Cooper, SJ; Dourish, CT; Clifton, PG (January 1992). "CCK antagonists and CCK-monoamine interactions in the control of satiety". Am. J. Clin. Nutr. 55: 291S–295S. PMID 1728842.
  5. Scarpignato, C; Varga, G; Corradi, C (1993). "Effect of CCK and its antagonists on gastric emptying". Journal of Physiology, Paris. 87 (5): 291–300. doi:10.1016/0928-4257(93)90035-r. PMID 8298606.
  6. Weller, A (Jul 2006). "The ontogeny of postingestive inhibitory stimuli: examining the role of CCK". Developmental Psychobiology. 48 (5): 368–79. doi:10.1002/dev.20148. PMID 16770766.
  7. Savastano, DM; Covasa, M (Oct 2007). "Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors". Physiology & Behavior. 92 (3): 434–42. doi:10.1016/j.physbeh.2007.04.017. PMID 17531277.
  8. "Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists". Journal of Medicinal Chemistry. 31: 2235–2246. doi:10.1021/jm00120a002.
  9. EP 1492540
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.